Wellbutrin XL Paragraph IV Filing
This article was originally published in The Pink Sheet Daily
Executive Summary
The first ANDA with a Paragraph IV certification for GlaxoSmithKline's Wellbutrin XL was filed Sept. 21, according to FDA's Nov. 17 update of Paragraph IV filings
You may also be interested in...
Abbott Buys Remaining Stake In Mavik And Tarka From Aventis For $300 Mil.
Abbott originally obtained marketing rights for the two cardiovascular drugs under a 1991 licensing agreement. Abbott expects peak sales to reach $700 mil. (versus $200 mil.-plus in 2003). The sale is not related to the Sanofi merger, Aventis says, but rather is part of an effort to divest underperforming brands.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.